A Phase 2 Multi-Center Study To Evaluate The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist In Adults With Type 2 Diabetes And Overt Nephropathy

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 226 participants.

Also called NCT01712061

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 226 participants (enrolled count) (from the registry)
Sponsor
  • Pfizer Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01712061
  • EudraCT 2012-003332-23
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Australia, Canada, Germany, Hong Kong SAR China, Italy, Malaysia, Peru, Poland, Puerto Rico, Romania, South Korea, Spain (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01712061. Randomized; double masking; primary purpose treatment. Start 2012-12 (registry gives no type); primary completion 2014-09 (actual). Results posted on 2015-10-21.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Phase 2 Multi-Center Study To Evaluate The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist In Adults With Type 2 Diabetes And Overt Nephropathy
Condition
Diabetic Nephropathy
Intervention (Drug)
PF-04634817
Intervention (Drug)
Placebo
Lead sponsor
Pfizer (class: industry)

Record details

Record id
cardio:ct-nct01712061
Content hash
b675c4b330e2c6b7e1cbd8c0a1d5a67d869285e61c6ebd3937f59109945f50cb